Oborska, Iwona
Amplyx Pharmaceuticals (United States)
2 papers on CoChat
Most cited papers
- Verified
Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial
Vazquez, J. A., Pappas, P. G., Boffard, K., Paruk, F., Bien, P. A., Tawadrous, M., Ople, E., Wedel, P., Oborska, I., & Hodges, M. R. (2023) · Antimicrobial Agents and Chemotherapy
Antifungal resistance and susceptibilityFungal Infections and Studies
Cited by 92
- Verified
Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial
Pappas, P. G., Vazquez, J. A., Oren, I., Rahav, G., Aoun, M., Bulpa, P., Ben-Ami, R., Ferrer, R., Mccarty, T., Thompson, G. R., et al. (2023) · Journal of Antimicrobial Chemotherapy
Antifungal resistance and susceptibilityFungal Infections and Studies
Cited by 65
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free